Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the safety of administering intravenous (IV)
pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with
hematologic malignancies and stem cell transplant recipients. There will also be an
assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic
therapy.